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Rationale: Pulmonary infections can impair alveolar fluid clearance
(AFC), contributing to formation of lung edema. Effects of influenza
A virus (IAV) on AFC are unknown.
Objectives: To determine effects of IAV infection on AFC, and to
identify intercellular signaling mechanisms underlying influenza-
mediated inhibition of AFC.
Methods: BALB/c mice were infected intranasally with influenza
A/WSN/33 (10,000 or 2,500 focus-forming units per mouse). AFC
was measured in anesthetized, ventilated mice by instilling 5%
bovine serum albumin into the dependent lung.
Measurements and Main Results: Infection with high-dose IAV resulted
in a steady decline in arterial oxygen saturation and increased lung
water content. AFC was significantly inhibited starting 1 hour after
infection, and remained suppressed through Day 6. AFC inhibition at
early time points (1–4 h after infection) did not require viral
replication, whereas AFC inhibition later in infection was replica-
tion-dependent. Low-dose IAV infection impaired AFC for 10 days,
but induced only mild hypoxemia. High-dose IAV infection increased
bronchoalveolar lavage fluid ATP and UTP levels. Impaired AFC at
Day 2 resulted primarily from reduced amiloride-sensitive AFC,
mediated by increased activation of the pyrimidine-P2Y purinergic
receptor axis. However, an additional component of AFC impair-
ment was due to activation of A1 adenosine receptors and stimula-
tion of increased cystic fibrosis transmembrane regulator–mediated
anion secretion. Finally, IAV-mediated inhibition of AFC at Day 2
could be reversed by addition of b-adrenergic agonists to the AFC
instillate.
Conclusions: AFC inhibition may be an important feature of early IAV
infection. Its blockade may reduce the severity of pulmonary edema
and hypoxemia associated with influenza pneumonia.
Keywords: orthomyxovirus infections; pneumonia, viral; pulmonary
edema; ion transport; adenosine
Influenza A virus (IAV) causes a highly contagious, acute
respiratory disease in humans (1). Most IAV infections are
self-limiting, but pneumonia and cardiac complications can lead
to significant morbidity and mortality (1). Furthermore, novel,
highly virulent IAV strains can arise after genetic reassortment
between strains (antigenic shift) (1). The resultant IAV pan-
demics elicited devastating loss of life throughout the 20th
century, and have the potential to do so in the 21st (2). Antiviral
drugs are available for IAV, but may be of limited long-term
utility due to development of viral resistance mutants (1).
Vaccination remains central to IAV control, but continued
antigenic drift necessitates the development of new vaccines
each year. Moreover, its utility in the elderly has recently been
questioned (3).
To facilitate normal gas exchange and effective mucociliary
clearance in the lung, the depth of the thin layer of fluid that lines
the airspaces is tightly regulated, and is a direct reflection of the
ion transport function of the respiratory epithelium. Normally,
the dominant ion transport process of the bronchoalveolar
epithelium is active transport of sodium (Na1) ions from the
alveolar lining fluid (ALF) to the subepithelial interstitial space
(4). Na1 ions in the ALF enter epithelial cells by passive diffusion
through apical membrane epithelial Na1 channels (ENaC). The
favorable electrochemical gradient for Na1 influx is maintained
by the basolateral Na1/K1 ATPase, which uses the energy from
ATP hydrolysis to transport three intracellular Na1 ions into the
interstitial space in exchange for two extracellular potassium
(K1) ions. Chloride (Cl2) ions follow transepithelial Na1 move-
ment (via paracellular pathways and apical membrane cystic
fibrosis transmembrane regulator [CFTR] Cl2 channels) to
maintain electrical neutrality. Transport of NaCl creates a trans-
epithelial osmotic gradient, which causes water to move passively
from the ALF to the interstitium. Inhibition of the Na1 transport
process can result in formation of an excessive volume of ALF
and impairment of gas exchange (5).
Exposure of murine tracheal tissue to pneumotropic IAV or free
viral hemagglutinins has been shown to result in rapid inhibition of
active Na1 transport (within 60 min) (6). IAV has also been shown
to reduce ENaC activity in rat alveolar type II cells over a compa-
rable time period (7). However, it is not clear how these effects
correlate to those of IAV replication within the lung over a period of
several days, as would occur in an infected subject. We therefore
used a BALB/c mouse model to investigate the effects of IAV
infection on alveolar fluid clearance (AFC), which is an in vivo
measure of active transepithelial ion transport. Some of the results of
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Active transport of sodium ions by bronchoalveolar epi-
thelial cells drives alveolar fluid clearance (AFC), which is
crucial to efficient gas exchange in the lung.
What This Study Adds to the Field
Infection with influenza A virus has physiologically signif-
icant inhibitory effects on AFC in vivo in BALB/c mice,
which result from uridine diphosphate–mediated inhibition
of sodium transport and adenosine-mediated stimulation of
chloride secretion.
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Except where noted, all reagents were from Sigma-Aldrich (St. Louis,
MO). Amiloride, A77–1726 (EMD Biosciences, La Jolla, CA), genis-
tein, fluoxetine, glibenclamide, forskolin, CFTRinh-172 (EMD Bio-
sciences), and 8-cyclopentyl-1,3-dipropylxanthine (Tocris Bioscience,
Ellisville, MO) were reconstituted in dimethyl sulfoxide. Niflumic acid
was reconstituted in acetone. 4,49-Diisothiocyanostilbene-2,29-disulfonic
acid (DIDS) was reconstituted in 0.1 M potassium bicarbonate, pH 8.0.
Rho kinase (ROCK) inhibitor and XAMR-0721 (both EMD Bioscien-
ces), N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-
1H-purin-8-yl) phenoxy]-acetamide (MRS 1754; Tocris Bioscience),
and all other reagents used were reconstituted in normal saline.
Reagents were added to the AFC instillate from stock solution aliquots
immediately before instillation into mice, in a minimal volume of solvent
(1–10 ml/ml).
Preparation of Viral Inocula
Influenza A/WSN/33 (H1N1) virus (WSN [Wisconsin] virus; a mouse-
adapted H1N1 human IAV strain, which is pneumotropic after in-
tranasal inoculation [9]) was grown in Madin-Darby bovine kidney
cells, and its infectivity assayed by fluorescent-focus assay 24 hours
after inoculation of the NY3 fibroblast cell line (derived from signal
transducer and activator of transcription-12/– mice), as previously
described (10). Aliquots of WSN stocks, diluted identically to live
stocks, were inactivated by exposure to 1,800 mJ of radiation in
a Stratalinker UV crosslinker (Stratagene, La Jolla, CA) (10).
Infection of Mice
Pathogen-free, 8- to 12-week-old BALB/c mice of either sex (main-
tained in sterile caging) were infected intranasally with 50 ml influenza
A/WSN/33 under light ketamine/xylazine anesthesia, as previously
described (11). Mock-infected animals received 50 ml of virus diluent
(phosphate-buffered saline with 0.1% bovine serum albumin [BSA]).
In some experiments, mice were individually marked and weighed
daily. All mouse procedures were approved by the Institutional Animal
Care and Use Committee at Ohio State University.
AFC Measurements
AFC was measured as previously described (11), but with correction
for excess murine alveolar protein, as described in the supplemental
methods. In all studies, four ventilators were run concurrently (with the
procedure staggered by a 3-min interval). Data for each experimental
group were derived from a minimum of two independent infections.
We found no sex-associated difference in AFC rate in BALB/c mice.
Measurement of Bronchoalveolar Epithelial Permeability
AFC procedures were performed using a 5% BSA solution containing
0.16 mg/ml fluorescein isothiocyanate (FITC)–tagged albumin (Sigma-
Aldrich). The amount of FITC-albumin detectable in peripheral serum
at the end of the AFC procedure was measured at 520 nm (excitation,
487 nm) in a NanoDrop 1000 fluorescence spectrometer (Thermo
Scientific, Wilmington, DE) (12).
Measurement of Bronchoalveolar Lavage
Proinflammatory Mediators
Cytokines and chemokines were measured by ultrasensitive mouse
proinflammatory multiplex electrochemiluminescence assay (Meso
Scale Discovery, Gaithersburg, MD). Total nitrate/nitrite was mea-
sured by fluorometric assay (Cayman Chemical, Ann Arbor, MI).
Lactate dehydrogenase was measured by colorimetric assay (Cayman
Chemical). All assays were performed in accordance with manufac-
turer’s instructions.
Other Methods
All other methods were performed as previously described (10, 11).
Statistical Analyses
Descriptive statistics were calculated using Instat 3.05 (GraphPad
Software, San Diego, CA). Gaussian data distribution was verified by
the method of Kolmogorov and Smirnov. Differences between group
means were analyzed by analysis of variance, with Tukey-Kramer
multiple comparison post-tests. Correlations were calculated by Pear-
son’s linear correlation analysis. P , 0.05 was considered statistically
significant. All data are presented as mean 6 SEM.
RESULTS
Effects of IAV on Body Weight in BALB/c Mice
Mock infection had no effect on body weight in BALB/c mice
(Figure 1A). Intranasal infection with 10,000 focus-forming
units (FFU) per mouse of WSN virus (influenza A/WSN/33)
caused a significant decline in body weight beginning 2 days
after infection, together with ruffling of fur, hunched posture,
and reduced activity. By Day 5, mice had lost over 20% of
starting weight and appeared moribund. A further precipitous
decline in weight occurred between Days 5 and 6, necessitating
termination of studies by Day 6. These findings were compara-
ble to those previously reported for mice infected with this IAV
strain at this titer (13). Infection of mice with an equivalent dose
of ultraviolet (UV)-inactivated WSN virus had no effect on
body weight, whereas infection with a sublethal dose (2,500
FFU/mouse) of live virus only induced significant weight loss at
Days 1 and 2 after infection.
Despite inducing severe cachexia, infection with 10,000 FFU/
mouse WSN virus did not alter either serum albumin or
osmolality—a small increase in serum osmolality was detected
at Day 1, but this was probably related to water deprivation
associated with recovery from general anesthesia at Day 0, as it
was also observed in mock-infected mice at this time point (14)
(Figures E1A and E1B in the online supplement).
Effect of IAV on Peripheral Blood Oxygen Saturation
Mock infection had no effect on peripheral blood oxygen
saturation (SpO2) in conscious BALB/c mice. However, in-
fection with 10,000 FFU/mouse WSN virus resulted in mild
hypoxemia from Day 2 postinfection (Figure 1B). Hypoxemia
became particularly severe at Day 6, when mice were moribund.
This rapid progression of hypoxemia was similar to that
reported by Sidwell and colleagues in WSN virus–infected mice
(15). Infection with an equivalent dose of UV-inactivated WSN
virus had no effect on SpO2, whereas infection with 2,500 FFU/
mouse of live virus only induced significant hypoxemia at Days
1 and 2 after infection.
IAV Replication in Lungs of BALB/c Mice
IAV replication was detectable in lung homogenates at 1 day
after infection with 10,000 FFU virus and peaked at Day 2
(Figure 1C). Replication was significantly lower at Day 4, and
was comparable to Day 1 by 6 days after infection. Infection
with 2,500 FFU/mouse WSN virus resulted in similar replication
kinetics in mouse lungs, with significant viral titers detectable
out to Day 10. In mice infected with an equivalent dose of UV-
inactivated virus, titers at Day 2 were reduced by more than 4
logs—very limited residual replication (,140 FFU/g lung
weight) was detectable.
Effects of IAV on Lung Water Content
Infection with 10,000 FFU/mouse WSN virus for 1–6 days, or
with 2,500 FFU/mouse WSN virus for 1 to 8 days, resulted in
a significant increase in lung wet:dry weight ratios compared
with mock-infected mice (Figure 1D). There was a significant
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correlation (P , 0.005; r2 5 0.546; n 5 13) between mean lung
water content and mean SpO2 after WSN virus infection.
Effects of IAV on Bronchoalveolar Epithelial Integrity
Bronchoalveolar lavage (BAL) lactate dehydrogenase and pro-
tein content were not elevated above levels in mock-infected
mice until Day 6 after infection with 10,000 FFU/mouse WSN
virus (Figures E2A and E2B). Measurements of the flux of
FITC-conjugated BSA from the instillate to the bloodstream
over a 30-minute period confirmed that WSN virus does not
induce significant increases in alveolar permeability until 4 to
6 days after infection (Figure E2C). At these time points, small
amounts of murine albumin could also be detected in AFC
aspirates (Figure E2D).
An independent observer found no histopathologic evidence
of any epithelial cell death or sloughing of epithelium until Day
4 after WSN virus infection. Likewise, terminal deoxynucleo-
tidyl transferase–mediated dUTP nick end-labeling analysis
indicated that epithelial apoptosis was restricted to sporadic
small foci at Day 2 and was not widespread until Day 4 (Figures
E2E and E2F). IAV antigen was detected predominantly in
bronchiolar epithelium at Day 2, but widespread immunoreac-
tivity in alveolar epithelial cells and alveolar macrophages was
seen at Day 4 (Figures E2G and E2H).
Effect of IAV on BAL Proinflammatory Mediator Levels in
BALB/c Mice
Infection with 10,000 FFU/mouse WSN virus increased BAL
proinflammatory cytokine levels with comparable kinetics to
those of previous reports (16–18) (Figure E3). No change in
BAL nitrate/nitrite levels was detected at any time point (data
not shown).
Effects of IAV on AFC in BALB/c Mice
AFC was evaluated in live mice with normal oxygenation and
acid–base balance, as previously described (11). The basal AFC
rate in mice that were mock infected for 2 days was not different
from that in uninfected mice (Figure 2A), and was identical to
that which we have reported previously for BALB/c mice (11,
19, 20). AFC was significantly depressed (by 27% from the
mean rate in mock-infected mice) by Day 1 after infection with
10,000 FFU/mouse of WSN virus, and further decreased at Day
2 (by 52% from the mean rate in mock-infected mice). No
recovery of basal AFC rate was detected at Days 4 and 6
postinfection. The ENaC inhibitor amiloride (1.5 mM) reduced
the mean AFC rate to 12% in both mock-infected and WSN
virus–infected mice at Day 2 (Figure 2B). When mice were
challenged with an equivalent dose of UV-inactivated virus,
AFC was reduced at 2 and 4 days after infection, but not at
Days 1 or 6 (Figure 2C). However, the inhibitory effect of UV-
inactivated WSN virus on AFC at Days 2 and 4 was small and
significantly less than that induced by 10,000 FFU/mouse live
virus at the same time points (both P , 0.005).
Infection with 2,500 FFU/mouse of live WSN virus resulted
in a similar rapid decline in basal AFC rate (by 46% at Day 1
and 62% at Day 2) to that seen in mice infected with 10,000
FFU virus (Figure 2C). AFC remained significantly depressed
in these mice until Day 8 after infection, and did not fully
recover until Day 18. Finally, there was a significant correlation
between mean AFC rate and mean SpO2 (P , 0.001; r
2 5 0.652;
n 5 13) after WSN virus infection.
Because Kunzelmann and colleagues (6) had described very
rapid inhibitory effects of pneumotropic IAV on active Na1
transport by mouse tracheal tissue, we also examined the effects
of short-term challenge with WSN virus (10,000 FFU/mouse) on
AFC. Whereas mock infection had a small (but nonsignificant)
inhibitory effect upon AFC at 1 to 4 hours after infection, WSN
virus caused much greater AFC inhibition (Figure 2D). AFC
was reduced by 47% from the mean rate in mock-infected mice
at 1 hour after infection, and remained significantly impaired at
4 hours. Challenge with an equivalent dose of UV-inactivated
virus resulted in a comparable reduction in AFC at 1 to 4 hours
after infection. WSN virus–induced AFC inhibition at 1 hour after
infection could be completely reversed by the protein kinase C
inhibitor, bisindolylmaleimide 1 hydrochloride (BIM-1) (100 mM).
Figure 1. Influenza A WSN virus infection of BALB/c
mice. (A) Percentage change in body weight (BWT) after
mock infection (open triangles), infection with 10,000
focus-forming units (FFU) per mouse WSN virus (WSN
10) (solid circles), infection with 2,500 FFU/mouse WSN
virus (WSN 2.5) (solid triangles), or infection with 10,000
FFU/mouse ultraviolet (UV)-inactivated WSN (UV-WSN)
(open squares) virus (n 5 10 for mock-infected mice; n 5
15–60 for WSN-infected mice; n 5 10 for UV-WSN–
infected mice). #P , 0.0005 compared with Day 0 BWT.
(B) Effect of mock infection (open triangles), infection
with WSN 10 (solid circles), infection with WSN 2.5 (solid
triangles), or infection with 10,000 FFU/mouse UV-WSN
(open squares) on peripheral arterial O2 saturation (SpO2)
(n 5 9–20 for mock-infected mice; n 5 12–25 for WSN-
infected mice; n 5 10–30 for UV-WSN–infected mice).
*P , 0.05, #P , 0.0005, compared with Day 0 SpO2 for
the same group. (C) Replication of WSN virus in lung
homogenates after infection with WSN 10 (shaded bars)
or WSN 2.5 (solid bars) (n 5 5–13 per time point). #P ,
0.0005 compared with 10,000 FFU/mouse titer at the
same time point. (D) Effect of mock infection for 2 days
(M2), infection with WSN 10 (shaded bars), or infection
with WSN 2.5 (solid bars) on lung water content, as
measured by wet:dry ratio (n 5 5–8 per group). *P ,
0.05, **P , 0.005, #P , 0.0005, compared with un-
infected mice (U).
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Effect of IAV on BAL 59-Nucleotide Levels
Infection of BALB/c mice with the paramyxovirus respiratory
syncytial virus (RSV) results in increased release of de novo–
synthesized UTP into the bronchoalveolar space, which medi-
ates AFC inhibition (11, 20). BAL fluid from uninfected or
mock-infected mice contained equivalent levels of ATP and
UTP. Infection with 10,000 FFU/mouse of WSN virus resulted
in a significant increase in BAL levels of both ATP and UTP at
Days 1 and 2, but not Day 4 (Figure 3). BAL ATP and UTP
levels decreased again at Day 4 after infection.
Effect of Blockade of the Pyrimidine–Purinergic Receptor Axis
on IAV-mediated Inhibition of AFC at Day 2 after Infection
In order to determine the role of 59-nucleotide–mediated P2Y
purinergic receptor activation in mediating the inhibitory effects
of WSN virus on AFC, we evaluated mice infected with 10,000
FFU/mouse WSN virus at the Day 2 time point, when inhibition
of AFC was maximal, but epithelial damage was not yet severe.
We had previously demonstrated that none of the agents used in
this part of the study have any effect on basal AFC rate in
normal mice (11, 20).
The de novo pyrimidine synthesis inhibitor, A77–1726
(20 mM), reversed WSN virus–induced suppression of AFC at
Day 2 (Figure 4A) by stimulating amiloride-sensitive transport.
Dihydro-orotate dehydrogenase inhibitors, such as A77–1726,
also have nonspecific tyrosine kinase inhibitory activity (21).
However, the beneficial effect of A77–1726 on AFC at Day 2
was not replicated by the broad-spectrum tyrosine kinase
inhibitor, genistein (20 mM). Furthermore, blockade of IAV-
mediated AFC inhibition by A77–1726 was partially reversed by
20 mM uridine, which allows pyrimidine synthesis via a salvage
pathway, indicating that the A77–1726 block is specific to the
de novo pyrimidine synthesis pathway.
Volume-regulated anion channels (VRACs) have been
shown to mediate ATP release from respiratory epithelial cells
in vitro (22). WSN virus–mediated inhibition of AFC at Day 2
was partially blocked by the proposed VRAC inhibitor, fluox-
etine (10 mM) (23), and this block was reversed by 500 nM UTP
(Figure 4B). VRAC opening can be facilitated by Rho kinase
activation (24). The Rho kinase inhibitor (ROCKi) (50 mM)
also partially blocked inhibition of basal AFC at Day 2 after
WSN virus infection.
Functional evidence suggests that murine lung epithelial
cells express P2Y2 and P2Y6 purinergic receptors (25): activa-
tion of these receptors by 59-nucleotides (ATP/UTP and UDP,
respectively) results in impaired epithelial Na1 transport (26).
AFC at Day 2 after WSN virus infection was significantly
increased by apyrase (5 U/ml), which degrades ATP and UTP
to their monophosphate forms, but was unaffected by hexoki-
nase (5 U/ml with 10 mM glucose), which hydrolyzes ATP and
UTP to their diphosphate forms (27) (Figure 4C). UDP-
glucose-pyrophosphorylase (5 U/ml with 5 U/ml inorganic
pyrophosphatase and 10 mM glucose-1-phosphate), which
metabolizes UTP to UDP-glucose, also significantly increased
AFC at Day 2 (Figure 4C). This effect was lost in the absence of
inorganic pyrophosphatase, which provides the energy to drive
Figure 2. Effect of influenza A virus (IAV) infection on
alveolar fluid clearance (AFC). (A) Effect of mock in-
fection or infection with 10,000 FFU/mouse WSN virus
for 1–6 days on basal AFC (n 5 12 for uninfected mice
[U]; n 5 8 for mock-infected mice at Day 2 [M2]; n 5 10
for WSN-infected mice at Day 1; n 5 11 for WSN-
infected mice at Day 2; n 5 9 for WSN-infected mice at
Day 4; n 5 17 for WSN-infected mice at Day 6). *P ,
0.05, #P , 0.0005, compared with mock-infected mice.
(B) Effect of mock infection (open bars) or infection with
WSN 10 (solid bars) on AFC sensitivity to amiloride
(AMIL;1.5mM)atDay2 (n5 7–8pergroup,exceptn 5
11 for untreated, WSN-infected mice). DAMIL 5 %
mean basal AFC 2 % mean amiloride-insensitive AFC.
#P , 0.0005 compared with untreated, mock-infected
mice. (C) Effect of infection with 2,500 FFU/mouse live
WSN virus (solid circles) or 10,000 FFU/mouse UV-
inactivated WSN virus (open squares) on basal AFC (n 5
7–9 per time point). *P , 0.05, **P , 0.005, #P ,
0.0005, compared with mock-infected mice. (D) Effect
of mock infection (open bars), infection with 10,000
FFU/mouse WSN virus (solid bars), or infection with an
equivalent dose of UV-inactivated WSN virus (dark
shaded bars) for 1–4 hours on AFC (n 5 7–9 per group).
Also shown is the effect of the protein kinase C inhibitor,
bisindolylmaleimide1 hydrochloride (BIM-1) (100 mM)
(light shaded bars), on AFC at 1 hour after infection
with WSN 10 (n 5 10). Dotted line indicates mean AFC
rate in uninfected animals (n 5 8). *P , 0.05, **P ,
0.005, #P , 0.0005, compared with uninfected animals.
Figure 3. Effect of mock
infection for 2 days (M2)
or infection with influenza
A virus (IAV) for 1–4 days
on bronchoalveolar lavage
ATP (open bars) and UTP
(solid bars) levels (n 5 7–8
per group). Values are cor-
rected for lung water. **P ,
0.005, #P , 0.0005, com-
pared with uninfected ani-
mals (U).
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the otherwise fully reversible degradation of UTP. The P2Y
receptor antagonists, suramin and XAMR-0721 (both 200 mM),
also reversed the inhibitory effect of WSN virus on basal AFC
at Day 2 (Figure 4D); 1.5 mM amiloride completely inhibited
the effect of XAMR-0721 on AFC at Day 2.
Because UTP and ATP levels are both high in BAL fluid
from WSN virus–infected mice, relative to mock-infected mice
(see Figure 3), but hexokinase does not reverse WSN virus–
induced AFC inhibition, our data suggest that inhibition of
AFC by WSN virus at Day 2 is mediated by UDP acting on
epithelial P2Y6 receptors. Indeed, in uninfected BALB/c mice,
UDP was slightly more efficacious than UTP, and significantly
Figure 4. Effect of block-
ade of the nucleotide–puri-
nergic receptor axis on
influenza A virus (IAV)–me-
diated inhibition of alveo-
lar fluid clearance (AFC) at
Day 2 after infection. (A)
Effect of addition to the
AFC instillate of the de novo
pyrimidine synthesis inhib-
itor, A77–1726 (20 mM;
n 5 10) (solid bar), uridine
(20 mM; n 5 10) (dark
shaded bar), A77–1726
with uridine (n 5 9) (light
shaded bar), A77–1726
with 1.5 mM amiloride
(n 5 8) (diagonally hatched
bar), and genistein (20 mM;
n 5 6) (horizontally hatched
bar) on AFC at Day 2 (no
treatment, n 5 11). (B)
Effect of blockade of volume-
regulated anion channels
with fluoxetine (10 mM;
n 5 10) (solid bar), fluoxe-
tine with 500 nM UTP (n 5
7) (dark shaded bar), and
Rho kinase inhibitor (50
mM; n 5 9) (light shaded
bar) on AFC at Day 2 (no
treatment, n 5 11). (C)
Effect of purinolytic and
pyrimidinolytic enzymes,
apyrase (5 U/ml; n 5 12)
(solid bar), hexokinase




(both 5 U/ml; n 5 11) (light
shaded bar), and UDP-
glucose pyrophosphory-
lase without inorganic
pyrophosphatase (n 5 9)
(hatched bar) on AFC at
Day 2 (no treatment, n 5 11). AFC studies using hexokinase were
performed in the presence of 10 mM glucose. AFC studies using UDP-
glucose pyrophosphorylase were performed in the presence of 10 mM
glucose-1-phosphate. (D) Effect of P2Y receptor antagonists suramin
(200 mM; n 5 7) (solid bar), XAMR-0721 (200 mM; n 5 8) (dark shaded
bar), and XAMR-0721 with 1.5 mM amiloride (n 5 9) (light shaded bar)
on AFC at Day 2 (no treatment, n 5 11). Dotted line indicates mean
AFC rate in untreated, mock-infected animals (n 5 8). **P , 0.005, #P
, 0.005, compared with untreated, WSN-infected mice at Day 2.
Figure 5. Effect of influ-
enza A virus infection for
2 days on anion secretion
in BALB/c mice. (A) Effect
of mock infection or infec-
tion with WSN virus on
alveolar fluid clearance





(dark shaded bars), and
the Ca21-activated Cl2
channel inhibitors, niflumic
acid (light shaded bars) and
4,49-diisothiocyanostilbene-
2,29-disulfonic acid (DIDS)
(hatched bars) (all 100 mM),
at Day 2 (n 5 8–12 per
group). *P , 0.05, **P ,
0.005, #P , 0.0005, com-
pared with untreated mice
(open bars) of the same in-
fection status. (B) Effect of
mock infection or infection
with WSN virus on AFC in
Cl2-free (Na1 gluconate)
bovine serum albumin
(BSA) in the absence (open
bars) or presence (solid bars)
of CFTRinh-172 (100 mM)
at Day 2 (n 5 7–9 per
group, except n 5 11 for
untreated, WSN-infected
mice). #P , 0.0005 com-
paredwithuntreated,mock-
infected mice. (C) Effect of
mock infection or infection
with WSN virus on AFC
sensitivity to the 59 ectonu-
cleotidase inhibitor, a,b-
methyleneADP (100 mM)
(solid bars), the A1-AR an-
tagonist, 8-SPT (200 mM)
(dark shaded bars), the A1-
AR antagonist, DCPCX
(100 mM) (light shaded
bars), and the A2b-adeno-
sine receptor antagonist,
MRS 1754 (100 mM)
(hatched bars), at Day 2
(n 5 8–9 per group, ex-
cept n 5 11 for untreated,
WSN-infected mice). *P ,
0.05, **P , 0.005, com-
pared with untreated mice
(open bars) of the same
infection status. (D) Effect
of mock infection or infec-
tion with WSN virus on AFC in Cl2-free (Na1 gluconate) BSA in the
absence (open bars) or presence (solid bars) of 8-SPT (200 mM) at Day 2
(n 5 9–11 per group). #P , 0.0005, compared with untreated, mock-
infected mice. (E) Effect of 20 mM A77–1726 with 200 mM 8-SPT (n 5
8) (solid bar) and 20 mM A77–1726 with 100 mM CFTRinh-172 (n 5 8)
(shaded bar) on AFC at Day 2 (no treatment, n 5 11). Dotted line
indicates mean AFC rate in untreated, mock-infected animals (n 5 12).
#P , 0.0005 compared with untreated, WSN virus–infected mice.
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more effective than ATP-g-S (a nonhydrolyzable analog of
ATP) in inhibiting AFC (Figure E4).
Effect of IAV on Anion Secretion in BALB/c Mice
The CFTR Cl2 channel inhibitors, CFTRinh-172 and glibencla-
mide (both 100 mM), both inhibited AFC in mock-infected mice
to a similar degree (Figure 5A). This indicates that AFC is
normally in part dependent upon CFTR-mediated Cl2 absorp-
tion in BALB/c mice (which is in agreement with prior studies
[28]). At Day 2, both CFTRinh-172 and glibenclamide increased
the AFC rate to a level comparable to that in mock-infected,
CFTRinh-172–treated mice. Ca21-activated Cl2 channel inhib-
itors (niflumic acid and DIDS, both 100 mM) had no significant
effect on AFC at Day 2.
The AFC rate was significantly more negative in WSN virus–
infected mice at Day 2 than in mock-infected mice under
Cl2-free conditions (in which NaCl in the instillate is replaced
with Na1 gluconate), which maximize the electrochemical
gradient for Cl2 secretion into the ALF (29) (Figure 5B). This
increased fluid secretion could be reversed by CFTRinh-172.
The 59 ectonucleotidase inhibitor a, b-methyleneADP
(100 mM), which blocks degradation of ATP to adenosine in the
ALF (30), had an identical stimulatory effect on AFC to that of
CFTRinh-172 and glibenclamide at Day 2 (Figure 5C). The A1-
subtype adenosine receptor (A1-AR) antagonists, 8-SPT (200 mM)
and 1,3-dipropyl-8-cyclopentylxanthine (DCPCX) (100 mM), had
a similar stimulatory effect on AFC at Day 2, but the A2b-
adenosine receptor antagonist, MRS 1754 (100 mM), did not. 8-
SPT also blocked increased fluid secretion under Cl2-free con-
ditions in WSN virus–infected mice, confirming that increased Cl2
efflux via CFTR at Day 2 results from A1-AR activation (Figure
5D). Finally, concomitant blockade of IAV’s inhibitory effect on
amiloride-sensitive Na1 absorption (using A77–1726) and its
stimulatory effect on Cl2 secretion (using either 8-SPT or
CFTRinh-172) had an additive effect, restoring normal AFC to
infected mice (Figure 5E).
Taken together, these results indicate that impaired AFC at
Day 2 after WSN virus infection results partially from adeno-
sine activation of A1-AR and the subsequent stimulation of
CFTR-mediated Cl2 secretion (see schematic in Figure 6).
Effect of Adenylyl Cyclase Activation on WSN Virus–mediated
Inhibition of AFC at Day 2 after Infection
b-Agonists can improve AFC in animal models of lung injury
(31), and have shown promise prophylactically and therapeuti-
cally in humans with impaired AFC (32–34). However, IAV
desensitizes b-adrenergic receptor (AR) in airway smooth mus-
cle (35), and A1-AR activation reduces intracellular cAMP levels
(36). Both the adenylyl cyclase agonist, forskolin (50 mM), and the
b2-AR agonist, terbutaline (100 mM), increased mean AFC at
Day 2 by stimulating amiloride-sensitive transport (Figure 7).
These results indicate that, unlike after RSV infection (19), the
bronchoalveolar epithelium remains sensitive to b-agonist stim-
ulation in IAV-infected mice.
DISCUSSION
The AFC process is crucial to efficient gas exchange in the lung
(37), and patients with acute lung injury that have intact AFC
have lower morbidity and mortality than those with compro-
mised AFC (38). However, the effect of viral pathogens on
respiratory epithelial Na1 transport and AFC has not been
studied in detail. Exposure of murine tracheal tissue to intact
virus, or even viral antigens from pneumotropic IAV (6), results
in rapid inhibition of active Na1 transport (within 60 min). IAV
also reduces ENaC activity in rat alveolar type II cells over
a comparable time span (7). Nevertheless, it is not clear how
Figure 6. Proposed mechanism for inhibition of alveolar
fluid clearance (AFC) after influenza A virus (IAV) infection
of BALB/c mice. IAV infection results in increased release of
the 59-nucleotides, UTP and ATP, into the ALF. The UTP
metabolite, UDP, activates P2Y6-subtype purinergic recep-
tors, resulting in inhibition of amiloride-sensitive epithelial
Na1 channels (ENaC) and reduced active Na1 absorption.
Concurrently, released ATP is metabolized by 59 ectonu-
cleotidases to adenosine, which activates A1-subtype
adenosine receptors (A1-AR) and thereby stimulates bron-
choalveolar epithelial Cl2 secretion via the CFTR. To-
gether, reduced Na1 absorption and increased Cl2
secretion result in severe impairment of AFC. Points of
action of pharmacologic inhibitors used in the current
study are also indicated: A77–1726 inhibits de novo
pyrimidine synthesis; fluoxetine and ROCKi block opening
of volume-regulated ion channels, which are the proposed
release pathway for UTP; apyrase and UDP-glucose pyro-
phosphorylase (UDP-G-PP) prevent formation of UDP
from UTP (by promoting formation of UMP and UDP-
glucose from UTP, respectively); suramin and XAMR-0721
are P2Y purinergic receptor antagonists; amiloride inhibits
ENaC activity; metADO inhibits 59 ectonucleotidase–
mediated hydrolysis of ATP to adenosine; 8-SPT and
DCPCX are A1-adenosine receptor antagonists; CFTRinh-
172 and glibenclamide are CFTR Cl2 channel blockers.
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such short-term effects correlate to the effects of viral replica-
tion within epithelial cells over a period of several days, as
would happen in an infected subject.
Our current study is the first to demonstrate that any IAV
strain has physiologically significant inhibitory effects on AFC
in vivo. The short-term suppressive effect on AFC after in-
fection with WSN virus for 1–4 hours is similar to the previously
reported inhibitory effect of IAV on Na1 transport in mouse
tracheal tissue in vitro (6). Both effects can be induced by both
live and UV-inactivated inocula (and so do not require viral
replication), and both are mediated by activation of protein
kinase C. In contrast, the long-term inhibitory effect of WSN
virus on AFC requires active, high-level viral replication, and
appears to be primarily mediated by release into the ALF of
de novo–synthesized pyrimidine nucleotides and the subsequent
activation of P2Y receptors, which reduces amiloride-sensitive
AFC. This mechanism is similar to that described for RSV (11).
However, unlike in RSV bronchiolitis, an additional component
of net AFC impairment after long-term WSN virus infection
results from WSN virus stimulation of Cl2 secretion via A1-
AR–mediated activation of CFTR (Figure 6). This additional
component may account for our finding that blockade of the
purinergic nucleotide–P2Y receptor axis alone did not fully
restore normal AFC in WSN virus–infected mice at Day 2, and
may also explain why the AFC defect observed was more severe
than that seen in RSV infection (11).
Epithelial necrosis and apoptosis is a component of IAV
pneumonitis in mice (10), and the inhibitory effects of WSN virus
on AFC might therefore simply be a consequence of viral
cytopathic effect. However, our data indicate that the decline in
AFC after WSN virus infection is unlikely to result solely, or even
primarily, from destruction of the epithelial barrier by lytic viral
replication, because a decline in AFC was detectable before
evidence of significant epithelial cell death (either histologically
or by analysis of BAL fluid and epithelial permeability). More-
over, a variety of data indicate that the respiratory epithelium
retained its potential for normal AFC and was not necrotic,
merely functionally impaired, at Day 2 after WSN virus infection:
the absence of effect of WSN virus on amiloride-insensitive AFC
(which indicates that inhibitory effects of WSN virus on both
amiloride-sensitive and CFTR-mediated ion transport were se-
lective); the stimulatory effect of WSN virus on CFTR-mediated
fluid secretion under Cl2-free conditions (which demonstrates
that the bronchoalveolar epithelium remained capable of active
ion transport); and, most importantly, the ability of a variety of
pharmacologic agents with widely differing mechanisms of action
(b-agonists, de novo pyrimidine synthesis inhibitors, VRAC
inhibitors, P2Y receptor and AR antagonists, and enzymes that
catabolize UTP) to reverse the inhibitory effect of WSN virus on
amiloride-sensitive AFC at Day 2 within 30 minutes (the duration
of the AFC procedure).
Our results suggest that IAV infection induces increased
degradation of ALF ATP to adenosine, thereby activating A1-
AR and stimulating Cl2 secretion via CFTR. They further
suggest that, as in RSV infection (39), ectonucleotidase-medi-
ated extracellular ATP hydrolysis may be enhanced after WSN
virus infection. A stimulatory effect of IAV on anion secretion
by respiratory epithelial cells has not previously been described.
To our knowledge, there is also no previous report of adenosine
receptor activation in response to infection with any pulmonary
pathogen, although Factor and colleagues (40) have shown that
adenosine can inhibit AFC in normal mice by activating A1-AR
on respiratory epithelial cells; our findings are in agreement
with this study. A1-AR antagonists can block endotoxin-
induced lung injury (41) and prevent alveolar edema in
ischemia–reperfusion–induced lung injury (42), which suggests
that A1-AR activation is proinflammatory and contributes to
development of pulmonary edema in the inflamed lung. How-
ever, an antiinflammatory role for A1-AR activation has also
been described in adenosine-dependent pulmonary injury
(43, 44). It is currently unclear whether the overall effect of
adenosine in IAV infection is pro- or antiinflammatory.
Differences in expression of IAV receptors terminating in
a2,3-linked and a2,6-linked sialic acid residues between airway
epithelial cells from mice and humans (45) may result in
disparities in cellular tropism for IAV at different levels of
the respiratory tract (46), which may translate into divergent
pathogenesis. Nevertheless, our data suggest that reduced
capacity to clear bronchoalveolar fluid may be an unrecognized
component of the pathogenesis of IAV pneumonitis, which
contributes to development of pulmonary edema and hypox-
emia. Moreover, our findings suggest that inhibition of de novo
pyrimidine synthesis (and/or blockade of A1-AR activation)
might be of value therapeutically in alleviating hypoxemia in
IAV pneumonitis, as it is in RSV infection (47, 48).
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